Alopecia areata: review of epidemiology, pathophysiology, current treatments and nanoparticulate delivery system

Papers of special note have been highlighted as: • of interest

References

• 1. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin. Cosmet. Investig. Dermatol. 8, 397–403 (2015). • This type of systematic review is crucial for understanding the prevalence, risk factors and impact of alopecia areata on individuals and populations.
  MedlineGoogle Scholar
• 2. Rancan F, Afraz Z, Combadiere B, Blume-Peytavi U et al. Hair follicle targeting with nanoparticles. Nanotechnology in Dermatology. Springer (2013).95–107
  Google Scholar
• 3. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int. J. Dermatol. 35(1), 22–27 (1996).
  Medline CASGoogle Scholar
• 4. Safavi K. Prevalence of alopecia areata in the first national health and nutrition examination survey. Arch. Dermatol. 128(5), 702 (1992).
  Google Scholar
• 5. Safavi K, Muller H, Suman SA, Moshell VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 Through 1989. Mayo Clin. Proc. 70(7), 628–633 (1995).
  Medline CASGoogle Scholar
• 6. Mirzoyev SA, Schrum AG, Davis MDP. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J. Invest. Dermatol. 134(4), 1141–1142 (2014).
  Medline CASGoogle Scholar
• 7. Pratt CH, King LE Jr, Messenger et al. Alopecia areata. Nat. Rev. Dis. Primers. 3, 17011 (2017).
  MedlineGoogle Scholar
• 8. McElwee K Jr, Gilhar A, Tobin DJ et al. What causes alopecia areata? Exp. Dermatol. 22(9), 609–626 (2013).
  Medline CASGoogle Scholar
• 9. Gilhar A, Etzioni A, Paus R. Alopecia areata. N. Engl. J. Med. 366(16), 1515–1525 (2012).
  Medline CASGoogle Scholar
• 10. Rajabi F, Drake LA, Senna MM. Alopecia areata: a review of disease pathogenesis. Br. J. Dermatol. 179(5), 1033–1048 (2018).
  Medline CASGoogle Scholar
• 11. Azzawi S, Penzi LR, Senna MM. Immune privilege collapse and alopecia development: is stress a factor. Skin Appendage Disord. 4(4), 236–244 (2018).
  MedlineGoogle Scholar
• 12. Hordinsky MK. Treatment of alopecia areata: “what is new on the horizon?”. Dermatol. Ther. 24(3), 364–368 (2011).
  MedlineGoogle Scholar
• 13. Alsantali A. Alopecia areata: a new treatment plan. Clin. Cosmet. Investig. Dermatol. 4, 107–115 (2011).
  MedlineGoogle Scholar
• 14. Tosti A, Piraccini BM, Pazzaglia M. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J. Am. Acad. Dermatol. 49(1), 96–98 (2003).
  MedlineGoogle Scholar
• 15. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des. Dev. Ther. 13, 2777–2786 (2019).
  Medline CASGoogle Scholar
• 16. Mura S, Pirot F, Manconi M. Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J. Drug Target. 15(2), 101–108 (2007).
  Medline CASGoogle Scholar
• 17. Toll R, Jacobi U, Richter H. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J. Invest. Dermatol. 123(1), 168–176 (2004).
  Medline CASGoogle Scholar
• 18. Wosicka-Frąckowiak H, Cal K, Stefanowska J et al. Roxithromycin-loaded lipid nanoparticles for follicular targeting. Int. J. Pharm. 495(2), 807–815 (2015).
  Medline CASGoogle Scholar
• 19. Blume-Peytavi U, Vogt A. Human hair follicle: reservoir function and selective targeting. Br. J. Dermatol. 165(Suppl. 2), 13–17 (2011).
  Medline CASGoogle Scholar
• 20. Verma A, Jain A, Hurkat P. Transfollicular drug delivery: current perspectives. Res. Rep. Transdermal Drug Deliv. 5, 1 (2016). • Explores the current perspectives on delivering drugs through hair follicles, which can be a fascinating avenue for enhancing topical drug delivery.
  Google Scholar
• 21. Gupta S, Bansal R, Gupta S. Nanocarriers and nanoparticles for skin care and dermatological treatments. Indian Dermatol. Online J. 4(4), 267–272 (2013). • Delves into the world of nanocarriers and nanoparticles designed for skin care and dermatological treatments.
  MedlineGoogle Scholar
• 22. Lademann J, Richter H, Teichmann A. Nanoparticles--an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 66(2), 159–164 (2007).
  Medline CASGoogle Scholar
• 23. Surber KS, Ha C. Nanomedicine in dermatology: nanotechnology in prevention, diagnosis, and therapy. Nanosci. Nanotechnol. Hum. Health (2006). https://doi.org/10.1002/9783527692057.ch16 • Explores the diverse applications of nanomedicine in dermatology, covering everything from prevention and diagnosis to therapy.
  Google Scholar
• 24. Radtke M, Patzelt A, Knorr F. Ratchet effect for nanoparticle transport in hair follicles. Eur. J. Pharm. Biopharm. 116, 125–130 (2017).
  Medline CASGoogle Scholar
• 25. Thomas EA, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. Indian J. Dermatol. 53(2), 70–74 (2008).
  MedlineGoogle Scholar
• 26. Yadav D, Khandpur S, Ramaan M. Utility of horizontal sections of scalp biopsies in differentiating between androgenetic alopecia and alopecia areata. Dermatol. [BaselSwitzerland] 234(3–4), 137–147 (2018).
  MedlineGoogle Scholar
• 27. Alshahrani AA, Al-Tuwaijri R. Prevalence and Clinical Characteristics of Alopecia Areata at a Tertiary Care Center in Saudi Arabia. Dermatol. Res. Pract. 2020, 7194270 (2020).
  MedlineGoogle Scholar
• 28. Furue M, Yamazak S, Jimbow K, Tsuchida T et al. Prevalence of Dermatological Disorders in Japan: A Nationwide, Cross-Sectional, Seasonal, Multicenter, Hospital-Based Study. J. Dermatol. 38(4), 310–320 (2011).
  MedlineGoogle Scholar
• 29. Kyriakis KP, Paltatzidou K, Kosma E et al. Alopecia Areata Prevalence by Gender and Age. J. Eur. Acad. Dermatol. Venereol. 23(5), 572–573 (2009).
  Medline CASGoogle Scholar
• 30. Usatine RP, Smith MA, Mayeaux EJ. The Color Atlas and Synopsis of Family Medicine McGraw-Hill Professional (2019).
  Google Scholar
• 31. Elmaadawi Iman Hamed, Ohamed B M, Ibrahim Z A et al. “Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia.”. The Journal of Dermatological Treatment 29(5), 431–440 (2018).
  MedlineGoogle Scholar
• 32. Paus R, Slominski A, Czarnetzki BM. Is Alopecia Areata an Autoimmune-Response Against Melanogenesis-Related Proteins, Exposed by Abnormal MHC Class I Expression in the Anagen Hair Bulb? Yale J. Biol. Med. 66(6), 541–554 (1993).
  Medline CASGoogle Scholar
• 33. Ito T, Saathoff M, Ito N, Nickoloff B. Novel Aspects of Hair Follicle Immune Privilege and Their Relevance to Alopecia Areata. J. Invest. Dermatol. Blackwell Publishing Inc, U.S.02148 (2005).
  Google Scholar
• 34. Hunt N, McHale S. The Psychological Impact of Alopecia. BMJ 331(7522), 951–953 (2005).
  MedlineGoogle Scholar
• 35. Peters EM, Ericson ME, Seiffert HJ et al. Neuropeptide Control Mechanisms in Cutaneous Biology: Physiological and Clinical Significance. J. Invest. Dermatol. 126(9), 1937–19479 (2006).
  Medline CASGoogle Scholar
• 36. Peters EM. An In Vitro Model for the Exploration of Cutaneous Stress Responses: Substance P Inhibits Hair Growth, Induces Mast Cell Degranulation, Up-Regulates p75NTR Expression and Causes Immune Privilege Collapse In Vitro. J. Investig. Dermatol. 127, S109– (2007).
  Google Scholar
• 37. Botchkarev VA. Stress and the Hair Follicle: Exploring the Connections. Am. J. Pathol. 162(3), 709–712 (2003).
  MedlineGoogle Scholar
• 38. Xiao FL, Yang S, Liu JB et al. The Epidemiology of Childhood Alopecia Areata in China: A Study of 226 Patients. Pediatr. Dermatol. 23(1), 13–18 (2006).
  MedlineGoogle Scholar
• 39. Martinez-Mir A, Zlotogorski A, Gordon D et al. Scan for Linkage Reveals Evidence of Several Susceptibility Loci for Alopecia Areata. Am. J. Hum. Genet. 80(2), 316–3289 (2007).
  Medline CASGoogle Scholar
• 40. Azzawi S, Penzi LR, Senna MM. Immune Privilege Collapse and Alopecia Development: Is Stress a Factor. Skin Appendage Disord. 4(4), 236–244 (2018).
  MedlineGoogle Scholar
• 41. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int. J. Trichology 10(2), 51–60 (2018).
  MedlineGoogle Scholar
• 42. d'Ovidio R. Alopecia Areata: News on Diagnosis, Pathogenesis and Treatment. G. Ital. Dermatol. Venereol. 149(1), 25–45 (2014).
  MedlineGoogle Scholar
• 43. Harries MJ, Sun J, Paus R, King LE Jr. Management of Alopecia Areata. BMJ 341, c3671 (2010).
  Medline CASGoogle Scholar
• 44. Harries MJ, Sun J, Paus R, King LE Jr. Management of Alopecia Areata. BMJ 341, c3671 (2010).
  Medline CASGoogle Scholar
• 45. Brzezińska-Wcisło L, Bergler-Czop B, Wcisło-Dziadecka D, Lis-Święty A. New Aspects of the Treatment of Alopecia Areata. Postepy Dermatol. Alergol. 31(4), 262–265 (2014).
  MedlineGoogle Scholar
• 46. Saoji V, Kulkarni S, Madke B. Alopecia Areata Treated with Oral Azathioprine: A Case Series. Int. J. Trichology 11(5), 219–222 (2019).
  MedlineGoogle Scholar
• 47. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and Its Use in Hair Disorders: A Review. Drug Des. Dev. Ther. 13, 2777–2786 (2019). • Comprehensively examines minoxidil, a medication widely used for treating various hair disorders.
  Medline CASGoogle Scholar
• 48. Singh G, Lavanya M. Topical Immunotherapy in Alopecia Areata. Int. J. Trichology 2(1), 36–39 (2010).
  MedlineGoogle Scholar
• 49. Esen Salman K, KıvançAltunay I, Salman A. The Efficacy and Safety of Targeted Narrowband UVB Therapy: A Retrospective Cohort Study. Turk. J. Med. Sci. 49(2), 595–603 (2019).
  MedlineGoogle Scholar
• 50. Ohtsuki A, Hasegawa T, Komiyama E et al. 308-nm Excimer Lamp for the Treatment of Alopecia Areata: Clinical Trial on 16 Cases. Indian J. Dermatol. 58(4), 326 (2013).
  MedlineGoogle Scholar
• 51. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and Safety of a New Clobetasol Propionate 0.05% Foam in Alopecia Areata: A Randomized, Double-Blind Placebo-Controlled Trial. J. Eur. Acad. Dermatol. Venereol. 20(10), 1243–1247 (2006).
  MedlineGoogle Scholar
• 52. Lenane P, Macarthur C, Parkin PC, Krafchik B. Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children: A Randomized Clinical Trial. JAMA Dermatol. 150(1), 47–50 (2014).
  Medline CASGoogle Scholar
• 53. Majid I, Keen A. Management of Alopecia Areata: An Update. Br. J. Med. Pract. 5(3), (2012).
  Google Scholar
• 54. Zivkovich AH, Feldman SR. Are Ointments Better than Other Vehicles for Corticosteroid Treatment of Psoriasis? J. Drugs Dermatol. 8(6), 570–572 (2009).
  MedlineGoogle Scholar
• 55. Senyigit T, Ozcan I, Ozer O. Innovative Topical Formulations for Treatment of Dermatitis. Recent Pat. Inflamm. Allergy Drug Discov. 6(3), 186–201 (2016).
  Google Scholar
• 56. Simões A, Veiga F, Vitorino C, Figueiras A. A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach. J. Pharm. Sci. 107(10), 2653–2662 (2018).
  Medline CASGoogle Scholar
• 57. Bolzinge M-A, Briançon S, Pelletier J, Chevalier Y. Penetration of Drugs Through Skin, a Complex Rate-Controlling Membrane. Curr. Opin. Colloid Interface Sci. 17(3), 156–165 (2012).
  Google Scholar
• 58. Chowdhury MM, Rahman MH, Wahab MA. Efficacy of Combination Therapy for the Management Regime of Alopecia Areata. Mymensingh Med. J. 16(Suppl. 2), S19–S22 (2007).
  Medline CASGoogle Scholar
• 59. Patzelt A, Lademan J. Recent Advances in Follicular Drug Delivery of Nanoparticles. Expert Opin. Drug Deliv. 17(1), 49–60 (2020).
  Medline CASGoogle Scholar
• 60. Jeong WY, Kim S, Lee SY et al. Transdermal Delivery of Minoxidil Using HA-PLGA Nanoparticles for the Treatment in Alopecia. Biomater. Res. 23, 16 (2019).
  MedlineGoogle Scholar
• 61. Pavithran K. Erythema multiforme Following Topical Minoxidil. Indian J. Dermatol. Venereol. Leprol. 59(6), 313–314 (1993).
  Google Scholar
• 62. Nagai N, Iwai Y, Sakamoto A et al. Drug Delivery System Based on Minoxidil Nanoparticles Promotes Hair Growth in C57BL/6 Mice. Int. J. Nanomedicine 14, 7921–7931 (2019).
  Medline CASGoogle Scholar
• 63. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic Contact Dermatitis to Topical Minoxidil Solution: Etiology and Treatment. J. Am. Acad. Dermatol. 46(2), 309–312 (2002).
  MedlineGoogle Scholar
• 64. Yoon G, Park JW, Yoon IS. Solid Lipid Nanoparticles [SLNs] and Nanostructured Lipid Carriers [NLCs]: Recent Advances in Drug Delivery. J. Pharm. Investig. 43(5), 353–362 (2013).
  CASGoogle Scholar
• 65. Mathes C, Melero A, Conrad P et al. Nanocarriers for Optimizing the Balance Between Interfollicular Permeation and Follicular Uptake of Topically Applied Clobetasol to Minimize Adverse Effects. J. Control. Release 223, 207–214 (2016).
  Medline CASGoogle Scholar
• 66. Lademann J, Richter H, Teichmann A et al. Nanoparticles–an Efficient Carrier for Drug Delivery into the Hair Follicles. Eur. J. Pharm. Biopharm. 66(2), 159–164 (2007).
  Medline CASGoogle Scholar
• 67. Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations Based on Solid Lipid Nanoparticles [SLN] and Nanostructured Lipid Carriers [NLC] for Cutaneous Use: A Review. Eur. J. Pharm. Sci. 112, 159–167 (2018).
  Medline CASGoogle Scholar
• 68. Ferreira-Nunes R, Cunha-Filho M, Gratieri T, Gelfuso GM. Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles . Colloids Surf B Biointerfaces. 208, 112101 (2021). • This reference explores an innovative approach to hair loss treatment using spironolactone-loaded polymeric nanoparticles.
  Medline CASGoogle Scholar
• 69. Oliveira ACS, Oliveira PM, Cunha-Filho M, Gratieri T, Gelfuso GM. Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia. A.A.P.S. PharmSciTech 21(8), 305 (2020).
  Medline CASGoogle Scholar
• 70. Matos BN, Reis TA, Gratieri T, Gelfuso GM. Chitosan Nanoparticles for Targeting and Sustaining Minoxidil Sulphate Delivery to Hair Follicles. Int. J. Biol. Macromol. 75, 225–229 (2015).
  Medline CASGoogle Scholar
• 71. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal Delivery of Mixnoxidil with Block Copolymer Nanoparticles. J. Control. Release 97(3), 477–484 (2004).
  Medline CASGoogle Scholar
• 72. Roque LV, Dias IS. Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia. Skin Pharmacol. Physiol. 30(4), 197–204 (2017).
  Medline CASGoogle Scholar
• 73. Afiune LAF, Ushirobira CY, Barbosa DPP, de Souza P. Novel Iron Oxide Nanocarriers Loading Finasteride or Dutasteride: Enhanced Skin Penetration for Topical Treatment of Alopecia. Int. J. Pharm 587, 119709 (2020).
  Medline CASGoogle Scholar
• 74. Nagai N, Iwai Y, Sakamoto A et al. Drug Delivery System Based on Minoxidil Nanoparticles Promotes Hair Growth in C57BL/6 Mice. Int. J. Nanomedicine 14, 7921–7931 (2019).
  Medline CASGoogle Scholar
• 75. Minoxidil. J. Drug Target. 15(2), 101–108 (2007).
  Medline CASGoogle Scholar
• 76. Wang W, Chen L, Huang X, Shao A. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers. A.A.P.S. PharmSciTech 18(2), 509–516 (2017). • Explores how these nanoparticles can target and sustain the delivery of minoxidil sulfate specifically to hair follicles.
  Medline CASGoogle Scholar
• 77. Padois K, Cantiéni C, Bertholle V, Bardel C, Pirot F, Falson F. Solid Lipid Nanoparticles Suspension Versus Commercial Solutions for Dermal Delivery of Minoxidil. Int. J. Pharm. 416(1), 300–304 (2011).
  Medline CASGoogle Scholar
• 78. Hamishehkar H, Ghanbarzadeh S, Sepehran S. Histological Assessment of Follicular Delivery of Flutamide by Solid Lipid Nanoparticles: Potential Tool for the Treatment of Androgenic Alopecia. Drug Dev. Ind. Pharm. 42(6), 846–853 (2016).
  Medline CASGoogle Scholar
• 79. Angelo T, El-Sayed N, Jurisic M et al. Effect of Physical Stimuli on Hair Follicle Deposition of Clobetasol-Loaded Lipid Nanocarriers. Sci. Rep. 10(1), 176 (2020).
  Medline CASGoogle Scholar
• 80. Lin YK, Al-Suwayeh SA, Leu YL, Shen FM, Fang JY. Squalene-Containing Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Diphencyprone for Treating Alopecia Areata. Pharm. Res. 30(2), 435–446 (2013).
  Medline CASGoogle Scholar
• 81. Aljuffali IA, Sung CT, Shen FM, Huang CT, Fang JY. Squarticles as a Lipid Nanocarrier for Delivering Diphencyprone and Minoxidil to Hair Follicles and Human Dermal Papilla Cells. A.A.P.S. J. 16(1), 140–150 (2014).
  CASGoogle Scholar
• 82. Pelikh O, Keck CM. Hair Follicle Targeting and Dermal Drug Delivery with Curcumin Drug Nanocrystals-Essential Influence of Excipients. Nanomaterials [Basel] 10(11), (2010).
  Google Scholar
• 83. Thappa DM, Vijayikumar M. Alopecia Areata. Indian J. Dermatol. Venereol. Leprol. 67(4), 188 (2001).
  Medline CASGoogle Scholar
• 84. Avgerinou G, Gregoriou S, Rigopoulos D et al. Alopecia Areata: Topical Immunotherapy Treatment with Diphencyprone. J. Eur. Acad. Dermatol. Venereol. 22(3), 320–323 (2008). • Explores the use of diphencyprone in topical immunotherapy for alopecia areata.
  Medline CASGoogle Scholar
• 85. Barrón-Hernández YL, Tosti A. Bimatoprost for the Treatment of Eyelash, Eyebrow and Scalp Alopecia. Expert Opin. Investig. Drugs 26(4), 515–522 (2017).
  Medline CASGoogle Scholar
• 86. Kurosawa M, Nakagawa S, Mizuashi M, Kawamu SY. A Comparison of the Efficacy, Relapse Rate and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata. Dermatology 212(4), 361–3z65 (2006).
  Medline CASGoogle Scholar
• 87. Chartaux E, Joly P. [Long-Term Follow-Up of the Efficacy of Methotrexate Alone or in Combination with Low Doses of Oral Corticosteroids in the Treatment of Alopecia Areata Totalis or universalis]. Ann. Dermatol. Venereol. 137(8–9), 507–513 (2010).
  Medline CASGoogle Scholar
• 88. Weiss VC, Wes DP. Topical Minoxidil Therapy and Hair Regrowth. Arch. Dermatol. 121(2), 191–192 (1985).
  Medline CASGoogle Scholar
• 89. Fiedler VC, Buys CM. Immunohistochemical Characterization of the Cellular Infiltrate in Severe Alopecia Areata Before and After Minoxidil Treatment. Dermatologica 175(Suppl. 2), 29–35 (1987).
  MedlineGoogle Scholar
• 90. Khoury EL, Price VH, Abdel-Salam MM, Stern M, Greenspan JS. Topical Minoxidil in Alopecia Areata: No Effect on the Perifollicular Lymphoid Infiltration. J. Invest. Dermatol. 99(1), 40–47 (1992).
  Medline CASGoogle Scholar
• 91. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J. Am. Acad. Dermatol. 16(3 Pt. 2), 730–736 (1987).
  Medline CASGoogle Scholar
• 92. Olsen EA, Carson SC, Turney EA. Systemic Steroids with or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata. Arch. Dermatol. 128(11), 1467–1473 (1992).
  Medline CASGoogle Scholar
• 93. Iorizzo M, Tosti A. Treatments Options for Alopecia. Expert Opin. Pharmacother. 16(15), 2343–2354 (2015).
  MedlineGoogle Scholar
• 94. Lucky AW, Piacquadio DJ, Ditre CM et al. A Randomized, Placebo-Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss. J. Am. Acad. Dermatol. 50(4), 541–553 (2004).
  MedlineGoogle Scholar
• 95. Carnahan MC, Goldstein DA. Ocular Complications of Topical, Peri-ocular, and Systemic Corticosteroids. Curr. Opin. Ophthalmol. 11(6), 478–483 (2000).
  Medline CASGoogle Scholar
• 96. Buhl AE. Minoxidil's Action in Hair Follicles. J. Invest. Dermatol. 96(5), S73–74S (1991).
  Google Scholar
• 97. Fiedler-Weiss VC, Buys CM. Evaluation of Anthralin in the Treatment of Alopecia Areata. Arch. Dermatol. 123(11), 1491–1493 (1987).
  Medline CASGoogle Scholar
• 98. Coronel-Pérez IM, Rodríguez-Re EM, Camacho-Martínez FM. Latanoprost in the Treatment of Eyelash Alopecia in Alopecia Areata universalis. J. Eur. Acad. Dermatol. Venereol. 24(4), 481–485 (2010).
  Medline CASGoogle Scholar
• 99. Das S, Ghorami RC, Chatterjee T, Banerjee G. Comparative Assessment of Topical Steroids, Topical Tretenoin [0.05%] and Dithranol Paste in Alopecia Areata. Indian J. Dermatol. 55(2), 148–149 (2010).
  MedlineGoogle Scholar
• 100. Dermatol. Surg. 33(12), 1483–1487 (2007).
  MedlineGoogle Scholar
• 101. Al-Mutairi N. 308-nm Excimer Laser for the Treatment of Alopecia Areata in Children. Pediatr. Dermatol. 26(5), 547–550 (2009).
  MedlineGoogle Scholar
• 102. Kar BR, Handa S, Dogra S, Kumar B. Placebo-Controlled Oral Pulse Prednisolone Therapy in Alopecia Areata. J. Am. Acad. Dermatol. 52(2), 287–290 (2005).
  MedlineGoogle Scholar
• 103. Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch. Dermatol. 123(11), 1488–1490 (1987).
  Medline CASGoogle Scholar
• 104. Price VH. Topical minoxidil [3%] in extensive alopecia areata, including long-term efficacy. J. Am. Acad. Dermatol. 16(3 Pt. 2), 737–744 (1987).
  Medline CASGoogle Scholar
• 105. Rai AK. Minoxidil-induced hypertrichosis in a child with alopecia areata. Indian Dermatol. Online J. 8(2), 147–148 (2017).
  MedlineGoogle Scholar
• 106. Ucak H, Kandi B, Cicek D, Halisdemir N, Dertlıoğlu SB. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J. Dermatolog. Treat. 23(6), 410–420 (2012).
  Medline CASGoogle Scholar